DUBLIN, April 13, 2016 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a leading global pharmaceutical company today
announced that it has 10 presentations at the upcoming 68th
American Academy of Neurology (AAN) annual meeting taking place
April 15-21, 2016 in Vancouver, Canada. Among the highlights are
three platform presentations including post-stroke lower limb
spasticity in adults.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
"We are proud of the data being presented at AAN as it further
demonstrates our leadership and commitment to research and
development in neurology," said David
Nicholson, executive vice president and president of Global
R&D Brands at Allergan.
The scheduled times (noted in local Pacific Time) of the
presentations and locations at the Vancouver Convention Centre are as
follows:
Spasticity:
- "Muscle Selection Patterns for Injection of OnabotulinumtoxinA
in Adult Patients With Post-Stroke Lower-Limb Spasticity Influence
Outcome: Results From a Double-Blind, Placebo-Controlled Phase 3
Clinical Trial"
- Presenter: Theodore Wein
- Platform # 001, Session: S7: Stroke Clinical Trials
- Sat, 4/16 3:30-3:45pm
- "Sustained Benefit with Repeated Treatments of
OnabotulinumtoxinA in Post-Stroke Lower Limb Spasticity: 1-Year
Open-Label Final Results from a Double-Blind, Placebo-Controlled,
Phase 3 Trial"
- Presenter: Theodore Wein
- Platform # 002, Session: S7: Stroke Clinical Trials
- Sat, 4/16 3:45-4:00pm
- "Impact of Early Intervention With OnabotulinumtoxinA Treatment
in Adult Patients With Post-Stroke Lower Limb Spasticity"
- Presenter: Atul Patel
- Platform #006, Session: S31: Stroke Risk, Outcomes, and
Complications
- Tues, 4/19, 2:15-2:30pm
- "Baseline Demographics and Clinical Characteristics of Patients
Treated for Spasticity in the Adult Spasticity International
Registry (ASPIRE Study)"
- Authors: Francisco G, Bandari D, Bavikatte G, Jost W, Manack
Adams A, Largent J, Esquenazi
A
- Poster #296, Session: P3
- Mon, 4/18, 8:30am-7pm (author
attendance: 5:30-7 pm)
Chronic Migraine:
- "Perspectives of Adolescents/Young Adults on the Burden of
their Parent's Migraine: Results from the CaMEO Study"
- Authors: Buse D, Powers S, Gelfand A, VanderPluym J, Fanning K,
Reed M, Manack Adams A, Lipton R
- Poster #121, Session: P4
- Tues, 4/19, 8:30am-7pm (author
attendance: 5:30-7pm)
- "Family Impact of Migraine: Development of the Impact of
Migraine on Partners and Children Scale (IMPACS)"
- Authors: Lipton R, Buse D, Manack Adams A, Varon, S,
Fanning K, Reed ML
- Poster # 172, Session: P1
- Sat, 4/16, 8:30am-7pm (author
attendance: 5:30-7pm)
- "A Comparison Of The Chronic Migraine Epidemiology &
Outcomes (CaMEO) Study And American Migraine Prevalence And
Prevention (AMPP) Study: Demographics And Headache-Related
Disability"
- Authors: Buse D, Lipton R, Manack Adams A, Fanning K, Reed
M
- Poster # 167, Session: P1
- Sat, 4/16, 8:30am-7pm (author
attendance: 5:30-7pm)
- "Real-World Utilization and Safety of OnabotulinumtoxinA for
Chronic Migraine Headache Prophylaxis: Interim Analysis from an
Observational Study in the European Union"
- Authors: Matharu M, Pascual J, Nilsson Remahl I, Straube A,
Johannes C, Odom D, Gutierrez L, Andrews E, Lum A
- Poster # 209, Session: P2
- Sun, 4/17, 8:30am-5:30pm (author
attendance: 4-5:30pm)
Alzheimer's Disease:
- "Caregiver Distress Related to Neuropsychiatric Symptoms is
Reduced with Extended-Release Memantine – Cholinesterase Inhibitor
Combination in Patients with Moderate to Severe Alzheimer's
Disease"
- Authors: Atri A, Hendrix S, Ellison N, Otcheretko V, Edwards
J
- Poster # 219, Session: P2
- Sun, 4/17, 8:30am-5:30pm (author
attendance: 4-5:30pm)
- "Daily Functioning Benefits of Adding Memantine to Stable
Cholinesterase Treatment in Patients with Moderate to Severe
Alzheimer's Disease: A Post Hoc Pooled Factor Analysis"
- Authors: Alva G, Ellison N, Dass B, Hendrix S
- Poster # 218, Session: P2
- Sun, 4/17, 8:30am-5:30pm (author
attendance: 4-5:30pm)
About Allergan
Allergan plc (NYSE: AGN), headquartered
in Dublin, Ireland, is a unique,
global pharmaceutical company and a leader in a new industry model
– Growth Pharma. Allergan is focused on developing, manufacturing
and commercializing innovative branded pharmaceuticals,
high-quality generic and over-the-counter medicines and biologic
products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2015 (certain of such periodic public filings having been
filed under the "Actavis plc" name). Except as expressly required
by law, Allergan disclaims any intent or obligation to update these
forward-looking statements.
CONTACTS:
Investors:
Lisa
DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-announces-10-presentations-on-chronic-migraine-upper-and-lower-limb-spasticity-and-alzheimers-disease-at-the-american-academy-of-neurology-meeting-in-vancouver-300248924.html
SOURCE Allergan plc